Wednesday, December 23, 2009

Aseptic Processing: Validation

Abstract

Aseptic processing is a widely used methodology in the health care industry for the preparation of sterile materials. The term aseptic processing as it is applied in the pharmaceutical industry refers to the assembly of sterilized components and product in a specialized clean environment. The clean environment may be a conventional human scale classified clean rooms or an environment engineered to further reduce the likelihood of contamination by reducing (or as much as is possible eliminating) direct human contact with the product and components being assembled “aseptically.” The idea of sterile products manufactured aseptically is inherently contradictory, a demonstrably sterile product cannot be produced aseptically using even the most advanced technology available today. Nevertheless, on any given day millions of putatively sterile dosage form units are produced using aseptic techniques that in the literal sense are inadequate to achieve sterility. A sterile product is one that is free from all living organisms, whether in a vegetative or spore state. This is an absolute condition, something cannot be partially or nearly sterile, the presence of a single viable organism represents a failure of the product, and the systems (environment, equipment, and procedures) used to produce it. Asepsis, that state in which all aseptically filled sterile products are manufactured, cannot be established as “sterile.” Asepsis is commonly defined as a condition in which living pathogenic organisms are absent.

Putting aside the classical definitions, one must consider the real difficulty in establishing an aseptic environment, let alone a sterile one. The practitioner is left with a insurmountable task, to somehow create an environment free of any organisms, but also one (with the exception of isolators) in which personnel must be present to perform critical functions. The problem is further compounded if it recalled that personnel are considered the single greatest source of microbial contamination in aseptic processing. Recent experiments have shown that personnel clothed in new, sterile clean room garments slough viable contamination at a rate of roughly one viable particulate to 10,000 non-viable particles. During slow deliberate movements with the best possible clothing, operators will slough particulate and viable organisms. Therefore, the probability of human borne microbial contamination being released in the conventional clean room is one over the course of any reasonably long operational shift. With this fact in mind, how then is one to accomplish a truly sterile or even aseptic environment? Especially when we must consider that many organisms that are normally non-pathogenic, can under certain circumstances become opportunistically pathogenic. Among those circumstances are a debilitated condition of general health in the patient, or, as is increasingly common, immunological insufficiency due to age or pre-existing condition.

Other than the obvious considerations of proper facility design, sterilization validation, and sanitization procedures (all of which are discussed elsewhere in this encyclopedia), the focus of attention must be on the personnel and the activities which they must perform. These actions are broadly termed, aseptic technique, and like any other human activity they can be accomplished in a variety of ways. In order to better understand aseptic technique, some general guidance and examples of good and bad technique can be used to delineate what should and should not be permitted.

The fundamental concept behind every aseptic processing activity is that non-sterile objects must never touch sterile objects. This is often accomplished by the establishment of a “sterile field” in which the core activities are performed. All of the surfaces of the gowned human operator must be always considered non-sterile. Non-sterile objects including the operators hands must never be placed between the source of the air and a sterile object. The operators' hands and arms must always be kept at a level beneath that of open product containers. Sterile components should under no circumstances be touched directly with gloved hands, a sterilized tool should always used for this purpose. Since gloved hands and arms will enter the sterile field they must never touch walls, floors, doors, etc. Strenuous lifting and moving of tanks, trolleys, etc. must not be done by operators assigned to work within or near the sterile field, because the more strenuous the activity the higher the level of particle generation, and at least some of the particulate released by the operator will surely by viable microorganisms.

Some of the techniques to avoid include: reaching over exposed sterile objects to make adjustments beyond them; correcting a stopper feed problem with a gloved hand; touching face, eye shield, or any other non-sterile object with gloves; taking an air sample directly over open containers; continuously standing inside flexible partitions that mark the boundary of the sterile field; breaking up clumps of components with gloved hands. Each of these actions exposes the sterile objects to undue risk of contamination from the personnel. Certainly there are more ways to contaminate the “sterile field” than we can imagine. For this reason, the procedures used in and around the “sterile field” must be carefully defined and followed closely by all personnel. These procedures should follow the general principles outlined above and are evaluated in a media fill simulation and performed in an identical fashion during aseptic processing. It is beneficial to define in writing how each procedure is to be performed and train the operators in these exact procedures. View Section: View Article (PDF) View Article (PDF)

Validation of Active Pharmaceutical Ingredients

Validation of Active Pharmaceutical Ingredients Book Description

Much has happened in the area of bulk pharmaceutical good manufacturing practice (GMP) and validation since the first publication of Validation of Active Pharmaceutical Ingredients. Revised, updated, and expanded, this second edition includes new chapters addressing postapproval changes, technology transfer, international cGMP guidelines/FDA guidance progress, and facility inspection issues. The basic philosophy and principles of GMP and validation have not changed, but new terminology had been introduced, and old terminology had been better defined, improving the understanding of related concepts and principles. The book gives you a working knowledge of the regulatory process that will facilitate your organization's compliance with regulations.

Robin Goldstein has contributed to Validation of Active Pharmaceutical Ingredients as an author. Niles Elliot Goldstein is the founding rabbi of The New Shul in Greenwich Village, New York. He lectures widely on Jewish mysticism and spirituality and has taught at New York University and the Hebrew Union College-Jewish Institute of Religion. Goldstein is the national Jewish chaplain for the Federal Law Enforcement Officers Association and was the voice behind "Ask the Rabbi" on the Microsoft Network. His essays and poetry have appeared in "Newsweek, the "Los Angeles Times, and many other publications, and he is the author or editor of five previous books, including God at the Edge: Searchi

Publisher: Informa Healthcare
Author: Santoro, Robin Goldstein, Berry R Berry
Edition Number: 2
Language: English
ISBN:

1574911198

EAN:

9781574911190

No. of Pages: 588
Publish Date: 2008-01-31

A Practical Guide to Microbial Limit Methodologies




A Practical Guide to Microbial Limit Methodologies
In recent years, the field of pharmaceutical microbiology has experienced numerous technological advances, accompanied by the publication of new and harmonized compendial methods. It is therefore imperative for those who are responsible for monitoring the microbial quality of pharmaceutical/biopharmaceutical products to keep abreast of the latest changes. Microbial Limit and Bioburden Tests: Validation Approaches and Global Requirements guides readers through the various microbiological methods listed in the compendia with easy-to-follow diagrams and approaches to validations of such test methodologies.
Includes New and Updated Material
Now in its second edition, this work is the culmination of research and discussions with technical experts, as well as USP and FDA representatives on various topics of interest to the pharmaceutical microbiologist and those responsible for the microbial quality of products, materials, equipment, and manufacturing facilities. New in this edition is an entire chapter dedicated to the topic of biofilms and their impact on pharmaceutical and biopharmaceutical operations. The subject of rapid methods in microbiology has been expanded and includes a discussion on the validation of alternative microbiological methods and a case studyon microbial identification in support of a product contamination investigation.
Substantially updated and revised, this book assists readers in understanding the fundamental issues associated with pharmaceutical microbiology and provides them with tools to create effective microbial contamination control and microbial testing programs for the areas under their responsibility.

Validating Chromatographic Methods: A Practical Guide



Validating Chromatographic Methods brings order and Current Good Manufacturing Practices to the often chaotic process of chromatographic method validation. It provides readers with both the practical information and the tools necessary to successfully set up a new validation system or upgrade a current system to fully comply with government safety and quality regulations. The net results are validated and transferable analytical methods that will serve for extended periods of time with minimal or no complications.

This guide focuses on high-performance liquid chromatographic methods validation; however, the concepts are generally applicable to the validation of other analytical techniques as well. Following an overview of analytical method validation and a discussion of its various components, the author dedicates a complete chapter to each step of validation:

  • Method evaluation and further method development
  • Final method development and trial method validation
  • Formal method validation and report generation
  • Formal data review and report issuance

Templates and examples for Methods Validation Standard Operating Procedures, Standard Test Methods, Methods Validation Protocols, and Methods Validation Reports are all provided. Moreover, the guide features detailed flowcharts and checklists that lead readers through every stage of method validation to ensure success.

For scientists and technicians new to method validation, this guide provides all the information and tools needed to develop a top-quality system. For those experienced with method validation, the guide helps to upgrade and improve existing systems.

Method Validation in Pharmaceutical Analysis: A Guide to Best Practice


Hardcover: 418 pages
Publisher: Wiley-VCH (May 6, 2005) English ISBN-10: 3527312552 ISBN-13: 978-3527312559
File type : PDFFile
size : 2.9 MB
Book Description
Adopting a practical approach, the authors provide a detailed interpretation of the existing regulations (GMP, ICH), while also discussing the appropriate calculations, parameters and tests. The book thus allows readers to validate the analysis of pharmaceutical compounds while complying with both the regulations as well as the industry demands for robustness and cost effectiveness. Following an introduction to the basic parameters and tests in pharmaceutical validation, including specificity, linearity, range, precision, accuracy, detection and quantitation limits, the text focuses on a life-cycle approach to validation and the integration of validation into the whole analytical quality assurance system. The whole is rounded off with a look at future trends. With its first-hand knowledge of the industry as well as regulating bodies, this is an invaluable reference for analytical chemists, the pharmaceutical industry, pharmaceutists, QA officers, and public authorities.


Download link
http://www.filefactory.com/file/a4eb70/

Document creation and execution

  • Validation Master Plans
  • User Requirements
  • Functional Specifications
  • Design Documents
  • Factory Acceptance Tests
  • Impact Assessments
  • Installation Qualifications
  • Operational Qualifications
  • Controls / Automation Qualifications
  • Computer Systems Validation
  • Performance Qualifications
  • Disaster Recovery Procedures
  • SOP Development

Concept of Process Validation For Pharmaceutical Industry

Concept of validation
GMP-definition is the validation of "establishing documented evidence that establishes a high degree of certainty that a particular process will consistently a product that provides the previously established specifications and quality attributes are available."
Appropriate and complete documentation is recognized as crucial for the validation. Standard Operating Procedures (SOPs), production formulas, detailed documentation batch changeControl, experimental reporting systems, analytical documents, reports development, validation protocols and reports are an integral part of validation philosophy. The validation of the documentation provides a source of information for the ongoing operation of the plant and is a resource that is used in the subsequent process of development or modification activities.
All test activities will take a level of impact assessment to ensure that systems, services andProducts were determined directly affected by the test.
A revalidation program should be implemented on a permanent equipment on the revalidation requirements and change control.
Types of Validation
Prospective validation
Establishing documented evidence that a device / process or system to do what they do, on a pre-planned series of scientific investigations within the meaning of validation sets basedPlan.
Concurrent validation
Is used when an existing process can be shown to be in a state of control by use of tests on samples taken at strategic points in a process, and at the end of the process. All data are collected simultaneously with the implementation of the process, to demonstrate sufficient information to process reproducibility.
Retrospective Validation
Establishing documented evidence that a process does notwhat it purports to do, based on review and analysis of historical data.
Design Qualification (DQ)
The intent of the DQ is in the planning and commissioning process met with a number of mechanisms, including:
- Generation of User Requirement Specifications
- Verification of this type corresponding user requirement specifications.
- Supplier Evaluation / Audit
- Check the Challenge of the design by GMP audits
- Product Quality ImpactAssessment
- Specifying Validation documentation requirements of suppliers
- Agreements with the suppliers about the performance targets
- Factory Acceptance Test (FAT), Site Acceptance Test (SAT) and commissioning procedures
- Definition of construction and installation documentation) to assist with Installation Qualification (IQ.
Installation Qualification (IQ)
IQ is a proof that the equipment or system has been documented in developeddelivered and installed in accordance with design drawings, vendor recommendations and in-house requirements. Moreover, IQ, that a record of the main features of the equipment or system is installed, how available and ensure that they are supported by sufficient and appropriate documentation to implement satisfactory operation, maintenance and control of changes.
Operational Qualification (OQ)
OQ is documented proof that operates the facilityas provided in the above design, operation or approved acceptance range of equipment, as applicable. In cases where process steps are considered an appropriate placebo batch is used to demonstrate device functionality.
All new devices should be fully taken into service before the start of OQ to ensure that at least be sure to use the device, complete with all mechanical assembly and pre-qualification checks are that the device is fully functional and thatDocumentation is complete.
Performance Qualification (PQ)
The goal of PQ is documented proof that the equipment can always be achieved while producing the specifications for a longer period at a defined operating point, a product of the specified quality. The specification will make reference to process parameters, in-process and product specifications. PQ requires three product batches available for all acceptanceCriteria for in-process and product testing. For supply PQ requires the benefits of medium to fulfill all the data over a longer period of sampling.
The PQ documentation should be on standard manufacturing procedures and batch records and describe the methodology of sampling and testing to be.
What is Validated
General
All process steps, production equipment, systems and environment, directly relevant to the production ofsterile and non-sterile products must be formally confirmed.
All major packaging equipment and processes should be validated. This validation is less comprehensive.
All ancillary systems, which should have no direct effect on product quality to be qualified by a technical documentation on the extent of the system and how it works.
Facility
- Manufacturing Area Design.
- Personnel and material flow, etc.
Process Equipment andDesign
Process steps and equipment description. Ie dosing, formulation, packaging, washing equipment
and cleaning. etc
Utility Systems Design
Raw / steam cleaned, purified water, compressed air, air conditioning, vacuum, power, lighting, cooling water, wastewater, etc.
Computerized Systems Design
Information system, automated laboratory equipment, automated manufacturing equipment, electronic recordsetc
Cleaning validation (CV)
CV provides evidence documenting that a cleaning procedure for the reduction of effective pre-defined maximum allowable limits, all chemical and microbiological contamination by one piece of equipment or a production area for processing. The means for evaluating the effectiveness of cleaning includes cleaning and disinfecting surfaces, sampling and inspection of product residues, cleaning residues and bacteriaContamination.
The term CV is used to describe the analytical investigation of a cleaning or by bicycle. The validation protocol should be based on background documentation on the reasons for the "worst case" test, where it is proposed. It should also develop the criteria for acceptance, including chemical and microbiological specifications, limits of detection and the selection of sampling.
Method Validation (MV)
MVprovides documented evidence that the internally-developed test methods are accurate, robust, efficient, reproducible and repeatable. The validation protocol should be based on background documentation on the reasons for determining the method detection limit and sensitivity.
Computer Validation
Computer Validation is a proof to ensure systems are consistently documented in accordance with the predetermined specifications and quality functionAttributes throughout their lifecycle. Important aspects of this approach are) the validation of formal management design (through a specification process), system quality (through systematic review and testing, risk (through the identification and evaluation of new and critical functions) and lifecycle (through sustainable change Control).
If the equipment in embedded computer systems, the elements of the validation of computer controlled, can be carried out as part of the equipment IQ and OQProtocols.

Validation Findings in FDA Warning Letters 2008

The GMP news from 18 February 2009 comprised information on the FDA Warning Letters Report 2008, including the Top 5 deficiencies.

It did not cover deficiencies regarding validation (validation/qualification/calibration) though. This is due to the fact that the findings are listed according to the paragraphs in the 21 CFR 210/211, which does not contain a separate paragraph addressing (process) validation. For that reason the following information does provide an individual validation issues analysis:

In the 22 Warning Letters in the fiscal year 2008 issues regarding validation were criticised 15 times. Top of the list were deficiencies relative to process validation (9 Warning Letters). Five of the letters referred to deficiencies concerning solid dosage forms, 2 concerned semi-solid forms, one addressed radio pharmaceuticals, and one product classification remained unclear.

Two Warning Letters per subject covered issues like inappropriate validation of the sterilisation process, filter validation, "smoke studies" and cleaning validation the authority issued like

Exemplary findings for the issues mentioned above are:

Exclusion of validation batches without providing reasons within a retrospective validation
Missing sampling details in the validation plan
It seems like you did not understand the meaning of a cleaning validation
The cleaning validation master plan does not contain any "scientific rationale" for specific products, sampling locations and acceptance criteria
Swab surfaces are too small
Not all loading patterns were mapped in the validation of the sterilisation process
Inadequate Air Flow Pattern
Further deficiencies concerned issues like

An inadequate calibration of thermocouples
A Media Fill not representing a commercial process
Undocumented removal of filled vials within Media Fills
Conclusion: Although the subject validation is not specifically listed in the 21 CFR 210/211, it still is among the top deficiencies in the Warning Letters issued. Almost 70% of all letters contained one or several findings relative to this subject. 41% were related to process validation.

Validation of USP Methods

In the first supplement of the USP 32, the revised, general chapter <1225> - Validation of Compendial Methods - was published. This chapter describes the requisite performance characteristics that should be considered to prove the validation of a method in the case of its submission to the Pharmacopoeia.

It is striking that terms coming from ISO standards have also been incorporated, although the wording in pharmaceutical surroundings was until now oriented towards the ICH Guidelines, especially ICH Q2(R1).

This was also the topic of the publication entitled "Making Sense of Trueness, Precision, Accuracy, and Uncertainty" in the Pharmacopoeial Forum of May-June 2008. This article reviews the differences between the terms when used in ICH and ISO. It also states that the terms "trueness" and "uncertainty" do not even exist in the ICH and the USP. The conclusions drawn in this article are as follows: The terms should be clarified in the USP. These clarifications could easily be added to the General Chapters <1010> und <1225>. In the longer term, the USP encourages continued harmonisation of terminology among the involved parties (ISO, ICH, VIM - International Vocabulary of Metrology) and other interested parties.

In the revised chapter <1225> of the first supplement to USP 32, these terms have now been incorporated from ISO 5725-1 and ISO 3534-1.

And the term "reportable value", established from the OOS discussions in recent years, is now also incorporated in this USP chapter.

The requisite performance characteristics to be considered in validation of the types of methods in order to prove their suitability for the USP (accuracy, precision, specificity, detection limit, quantitation limit, linearity, range and ruggedness) remained unchanged.

And when is it necessary to revalidate? Revalidation may become necessary when a revised analytical method is submitted to the USP or when an established, general method is to be used for a new product or for a new starting material.

Pharmaceutical Master Validation Plan: The Ultimate Guide to FDA, GMP, and GLP Compliance.

Pharmaceutical Master Validation Plan: The Ultimate Guide to FDA, GMP, and GLP Compliance.
By Syed Imtiaz Haider
  • Publisher: Informa HealthCare
  • Number Of Pages: 208
  • Publication Date: 2001-12-27
  • ISBN-10 / ASIN: 1574443305
  • ISBN-13 / EAN: 9781574443301
  • Binding: Hardcover

Product Description:

The Master Validation Plan provides a roadmap to management for on-time start-up of facility operations, and validation of existing facilities, in compliance with GMP requirements. The lack of a comprehensive Master Validation Plan and well-documented validation procedures is the main reason that new drug, medical device, medical equipment, and related product applications are rejected by the FDA. In fact, only about 2% of the applications submitted by foreign pharmaceutical companies are approved each year. This thorough guide provides the needed solutions and guidance for both foreign and U.S. companies to achieve FDA compliance and authorization to market their products in the United States. Pharmaceutical Master Validation Plan: The Ultimate Guide to FDA, GMP, and GLP Compliance will allow you to more easily achieve satisfactory inspections, new medical product approval, minimize non-conformance, reduce rework and rejected lots, and avoid recall lots by developing and managing a Master Validation Plan. The accompanying CD allows users to input the template plan into their computers and tailor it to incorporate additional regulatory requirements specific to individual companies worldwide and print the required documents. Together, the book and CD contain everything required to develop and execute a successful Master Validation Plan based on FDA guidelines for the pharmaceutical industry, and allows the templates to be extended to diagnostic products, medical device, medical equipment, and biotech industry products.

DOWNLOAD LINK:

http://www.filefactory.com/file/6b6111/n/1574443305_zip